Table 3 Relative changes in the expression of gene signatures in response to the 2-week AI treatment of the HER2− and HER2+ tumours.

ESR1

− 23.06

1.54E−02

18.28

6.23E−01

9.18E−03

ERGs-GS

− 30.79

8.58E−14

− 21.96

2.85E−03

5.81E−02

DiLeoRBloss-GS

− 27.61

9.81E−10

− 30.64

1.41E−03

5.43E−01

JClinInvest2007RBloss-GS

− 26.11

5.47E−10

− 29.45

1.78E−03

4.72E−01

CIN70-GS

− 25.92

3.26E−10

− 28.69

1.81E−03

5.40E−01

E2F4activation-GS

− 25.26

4.54E−09

− 30.07

5.02E−03

3.13E−01

GGI-GS

− 23.67

1.78E−09

− 27.85

1.19E−03

3.40E−01

ERTarget27-GS

− 17.80

1.32E−15

− 11.41

3.32E−02

1.71E−02

E2FmotifCellCycleAssociated-GS

− 16.75

5.71E−09

− 21.72

2.00E−03

1.31E−01

E2Factivation-GS

− 14.45

2.25E−07

− 18.20

1.93E−02

2.62E−01

AURKA-GS

− 13.91

1.08E−07

− 15.45

3.94E−03

6.10E−01

Gene70-GS

− 9.37

1.97E−07

− 12.34

6.76E−03

1.98E−01

SET-GS

− 9.34

1.55E−05

− 2.08

5.69E−01

8.73E−03

PTEN-GS

− 7.55

1.44E−06

− 8.81

3.62E−02

5.38E−01

ESR1.2-GS

− 5.82

3.01E−04

− 0.46

8.49E−01

1.10E−02

ESR1.1-GS

− 5.40

2.99E−03

0.29

9.29E−01

1.50E−02

MYC-GS

− 4.36

1.98E−04

− 3.54

2.24E−01

6.02E−01

IGF1-GS

− 4.15

4.59E−04

− 4.07

7.76E−02

9.58E−01

VEGF-GS

− 3.85

3.33E−02

− 0.21

9.48E−01

1.09E−01

GDNF-GS

− 3.41

1.40E−01

− 5.23

4.25E−01

5.71E−01

obesity-GS

− 3.08

2.40E−02

− 1.72

5.64E−01

4.55E−01

E2F3-GS

− 2.89

5.01E−05

− 3.79

2.62E−02

3.45E−01

PI3K-GS

− 1.80

3.19E−03

− 3.11

6.69E−02

1.23E−01

SRC-GS

− 1.69

2.83E−01

− 1.62

6.46E−01

9.74E−01

AKT/mTOR-GS

− 1.62

4.57E−02

− 1.95

3.31E−01

7.51E−01

RAS-GS

− 1.47

1.93E−01

− 0.47

8.51E−01

5.04E−01

BetaCatenin-GS

− 1.28

3.83E−01

0.04

9.91E−01

5.07E−01

WntTarget34-GS

− 0.30

8.90E−01

− 2.56

6.50E−01

4.28E−01

ERBB2-GS

0.27

8.88E−01

− 0.88

8.60E−01

6.55E−01

PIK3CA-GS

0.39

7.20E−01

1.77

3.99E−01

3.42E−01

STAT1-GS

0.79

8.27E−01

− 7.73

2.98E−01

6.99E−02

CASP3-GS

1.37

5.57E−01

− 1.18

8.48E−01

3.82E−01

Bcell-GS

1.71

6.92E−01

− 7.38

3.51E−01

7.71E−02

MacTh1-GS

2.72

4.94E−01

0.20

9.79E−01

6.38E−01

Tcell-GS

2.83

5.38E−01

− 6.13

4.73E−01

1.12E−01

Inflammatory-GS

2.86

4.92E−01

− 4.80

5.15E−01

1.55E−01

Immune.1-GS

3.07

5.24E−01

− 5.34

6.10E−01

1.49E−01

MAPK-GS

3.21

6.59E−03

1.94

5.02E−01

4.22E−01

Stroma.2.PLAU-GS

6.57

4.65E−02

4.54

5.14E−01

6.34E−01

Stroma.1-GS

20.71

1.17E−02

21.87

1.61E−01

9.18E−01

TP53-GS

29.90

6.45E−10

29.38

5.59E−03

9.44E−01

PAGs

− 4.40

6.44E−06

− 6.23

2.06E−02

1.37E−01